<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DIGOXIN <img border="0" src="../images/pr.gif"/></span><br/>(di-jox'in)<br/><span class="topboxtradename">Lanoxicaps, </span><span class="topboxtradename">Lanoxin<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">cardiac glycoside</span>; <span class="classification">antiarrhythmic</span><br/><b>Pregnancy Category: </b>A<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.05 mg, 0.1 mg, 0.2 mg capsules; 0.125 mg, 0.25 mg, 0.5 mg tablets; 0.05 mg/mL elixir; 0.25 mg/mL, 0.1 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Widely used cardiac glycoside of <i>Digitalis lanata</i>. Acts by increasing the force and velocity of myocardial systolic contraction (positive inotropic effect). It also decreases
         conduction velocity through the atrioventricular node. Action is more prompt and less prolonged than that of digitalis and
         digitoxin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Increases the contractility of the heart muscle (positive inotropic effect).</p>
<h1><a name="uses">Uses</a></h1>
<p>Rapid digitalization and for maintenance therapy in CHF, atrial fibrillation, atrial flutter, paroxysmal atrial tachycardia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Digitalis hypersensitivity, ventricular fibrillation, ventricular tachycardia unless due to CHF. Full digitalizing dose not
         given if patient has received digoxin during previous week or if slowly excreted cardiotonic glycoside has been given during
         previous 2 wk.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency, hypokalemia, advanced heart disease, acute MI, incomplete AV block, cor pulmonale; hypothyroidism; lung
         disease; pregnancy (category A), lactation, premature and immature infants, children, older adults, or debilitated patients.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Digitalizing Dose</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1015 mcg/kg (1 mg) in divided doses over 2448 h <span class="rdroute">IV</span> 1015 mcg/kg (1 mg) in divided doses over 24 h<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>, 4060 mcg/kg; <i>210 y</i>, 2040 mcg/kg; &gt;<i>10 y</i>, 1015 mcg/kg (1.52 mg)<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO/IV</span> 3050 mcg/kg<br/><span class="rdage">Premature neonate:</span> <span class="rdroute">PO/IV</span> 20 mcg/kg<br/><br/><span class="indicationtitle">Maintenance Dose</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 0.10.375 mg/d<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span>
<i>, 7.59 mcg/kg/d; <i>210 y</i>, 67.5 mcg/kg/d; &gt;<i>10 y</i>, 0.1250.25 mg/d<br/><span class="rdage">Neonate:</span> <span class="rdroute"></span> 67.5 mcg/kg/d<br/><span class="rdage">Premature neonate:</span> <span class="rdroute"></span> 3.75 mcg/kg/d<br/></i></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give without regard to food. Administration after food may slightly delay rate of absorption, but total amount absorbed is
            not affected.
         </li>
<li>Crush and mix with fluid or food if patient cannot swallow it whole.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted or diluted in 4 mL of sterile water, D5W, or NS (less diluent may cause precipitation).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give each dose over at least 5 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span>
<b>Dobutamine,</b>
<b>doxapram.</b>
<span class="incompattype">Y-site:</span>
<b>Amiodarone.</b>
</p>
<ul>
<li>Monitor IV site frequently. Infiltration of parenteral drug into subcutaneous tissue can cause local irritation and sloughing.</li>
</ul>
</td>
</tr>
</table>
<ul>
<li>Store tablets, elixir, and injection solution at 25° C (77° F) or at 15°30° C (59°86°
            F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Fatigue, muscle weakness, headache, facial neuralgia, mental depression, paresthesias, hallucinations, confusion, drowsiness,
      agitation, dizziness. <span class="typehead">CV:</span> Arrhythmias, hypotension, <span class="speceff-life">AV block</span>. <span class="typehead">Special Senses:</span> Visual disturbances. <span class="typehead">GI:</span> Anorexia, <span class="speceff-common">nausea,</span> vomiting, diarrhea. <span class="typehead">Other:</span> Diaphoresis, recurrent malaise, dysphagia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification">antacids</span>, <b>cholestyramine,</b>
<b>colestipol</b> decrease digoxin absorption; <span class="classification">diuretics</span>, <span class="classification">corticosteroids</span>, <b>amphotericin B,</b>
<span class="classification">laxatives</span>, <b>sodium polystyrene sulfonate</b> may cause hypokalemia, increasing the risk of digoxin toxicity; <b>calcium IV</b> may increase risk of arrhythmias if administered together with digoxin; <b>quinidine,</b>
<b>verapamil,</b>
<b>amiodarone,</b>
<b>flecainide</b> significantly increase digoxin levels, and digoxin dose should be decreased by 50%; <b>erythromycin</b> may increase digoxin levels; <b>succinylcholine</b> may potentiate arrhythmogenic effects; <b>nefazodone</b> may increase digoxin levels. <span class="typehead">Herbal:</span>
<b>Ginseng</b> increase digoxin toxicity; <b>ma huang,</b>
<b>ephedra</b> may induce arrhythmias. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 70% PO tablets; 90% PO liquid and capsules. <span class="typehead">Onset:</span> 12 h PO; 530 min IV. <span class="typehead">Peak:</span> 68 h PO; 15 h IV. <span class="typehead">Duration:</span> 34 d in fully digitalized patient. <span class="typehead">Distribution:</span> Widely distributed; tissue levels significantly higher than plasma levels; crosses placenta. <span class="typehead">Metabolism:</span> Approximately 14% in liver. <span class="typehead">Elimination:</span> 8090% excreted by kidneys; may appear in breast milk. <span class="typehead">Half-Life:</span> 3444 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Take apical pulse for 1 full min, noting rate, rhythm, and quality before administering drug.</li>
<li>Withold medication and notify physician if apical pulse falls below ordered parameters (e.g., 
         </li><li>Be familiar with patient's baseline data (e.g., quality of peripheral pulses, blood pressure, clinical symptoms, serum electrolytes,
            creatinine clearance) as a foundation for making assessments.
         </li>
<li>Lab tests: Baseline and periodic serum digoxin, potassium, magnesium, and calcium. Draw blood samples for determining plasma
            digoxin levels at least 6 h after daily dose and preferably just before next scheduled daily dose.
         </li>
<li>Monitor for S&amp;S of drug toxicity: In children, cardiac arrhythmias are usually reliable signs of early toxicity. Early indicators
            in adults (anorexia, nausea, vomiting, diarrhea, visual disturbances) are rarely initial signs in children.
         </li>
<li>Monitor I&amp;O ratio during digitalization, particularly in patients with impaired renal function. Also monitor for edema daily
            and auscultate chest for rales.
         </li>
<li>Monitor serum digoxin levels closely during concurrent antibioticdigoxin therapy, which can precipitate toxicity because
            of altered intestinal flora.
         </li>
<li>Observe patients closely when being transferred from one preparation (tablet, elixir, or parenteral) to another; when tablet
            is replaced by elixir potential for toxicity increases since <img src="../images/special/greaterorequal.gif"/>30% of drug
            is absorbed.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician if pulse falls below 60 or rises above 110 or if you detect skipped beats or other changes in rhythm,
            when digoxin is prescribed for atrial fibrillation.
         </li>
<li>Suspect toxicity and report to physician if any of the following occur: Anorexia, nausea, vomiting, diarrhea, or visual disturbances.</li>
<li>Weigh each day under standard conditions. Report weight gain &gt;1 kg (2 lb)/d.</li>
<li>Take digoxin <small>PRECISELY</small> as prescribed, do not skip or double a dose or change dose intervals, and take it at same time each day.
         </li>
<li>Do not to take OTC medications, especially those for coughs, colds, allergy, GI upset, or obesity, without prior approval
            of physician.
         </li>
<li>Continue with brand originally prescribed unless otherwise directed by physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>